Searchable abstracts of presentations at key conferences in endocrinology

ea0046p7 | (1) | UKINETS2016

Evaluation of quality of life after each cycle in patients treated with Peptide Receptor Radionuclide Therapy (PRRT)

Mateo-Vito Ivy , Amlani Ashik , Leshen Rebelidad , Mcmeekin Helena , Davis Neil , Navalkissoor Shaunak

Background: NET-related symptoms such as flushing and diarrhoeas as well as disease related worries reduce quality of life in patients with neuroendocrine tumours (NETs). Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to prolong survival. However quality of life data post PRRT is lacking.Aim: To evaluate the symptoms prevalence, intensity and their relation to quality of life in patients receiving PRRT...

ea0052p36 | (1) | UKINETS2017

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

Nicolas Guillaume , Baum Richard , Herrmann Ken , Lassmann Michael , Hicks Rodney , Haug Alexander , Navalkissoor Shaunak , Oberwittler Heike , Wang Tiffany , Wild Damian

Introduction: Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin receptor (SSTR) agonists is highly effective and has become an integral part of neuroendocrine tumour (NET) treatment. However, tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. OPS201 (DOTA-JR11) is a very promising next-generation SSTR antagonist selective for SSTR2 (expressed by NETs). This phase 1/2, international, single-...

ea0090p141 | Pituitary and Neuroendocrinology | ECE2023

177Lu DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in advanced Phaeochromocytomas and paragangliomas (PPGL) – a single centre experience at a ENETS Centre of Excellence

Mansukhbhai Shekhda Kalyan , Armeni Eleni , Hayes Aimee , Caplin Martyn , Toumpanakis Christos , Mandair Dalvinder , Quigley Ann-Marie , Navalkissoor Shaunak , Grossman Ashley , Khoo Bernard

Introduction: Phaeochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumours with no standardised protocol for treatment. 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is an emerging treatment option for patients with metastatic and/or inoperable PPGL, and with low toxicity. We present our experience with PRRT in advanced PPGL, treated in a ENETS Centre of Excellence.Materials and Methods: 165 patients with...